Meeting
2023 ASCO Annual Meeting
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
Authors
Rinath Jeselsohn
Dana-Farber Cancer Institute, Boston, MA
Rinath Jeselsohn , Lu Chen , Nayan Chaudhary , Jorge Martinalbo , Peter A. Fasching , Marc Hafner , Patricia Luhn , Alberto J. Montero , Pablo Diego Pérez-Moreno , Seth Andrew Wander , Kevin Kalinsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1062)
DOI
10.1200/JCO.2023.41.16_suppl.1062
Abstract #
1062
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
First Author: Rachel M. Layman
Poster
2022 ASCO Annual Meeting
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
First Author: Thomas Meyskens
Poster
2020 ASCO Virtual Scientific Program
Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
First Author: Mario Campone
Poster
2023 ASCO Annual Meeting
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.
First Author: Aditya Bardia